R
Robert C. Owens
Researcher at Maine Medical Center
Publications - 64
Citations - 8966
Robert C. Owens is an academic researcher from Maine Medical Center. The author has contributed to research in topics: Antimicrobial stewardship & Clostridium difficile. The author has an hindex of 30, co-authored 64 publications receiving 8499 citations. Previous affiliations of Robert C. Owens include University of Vermont.
Papers
More filters
Journal ArticleDOI
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship
Timothy H. Dellit,Robert C. Owens,John E. McGowan,Dale N. Gerding,Robert A. Weinstein,John P. Burke,W. Charles Huskins,David L. Paterson,Neil O. Fishman,Christopher F. Carpenter,Patrick J. Brennan,Marianne Billeter,Thomas M. Hooton +12 more
TL;DR: This research presents a meta-analysis of 125 cases of central giant cell apoptosis, a type of cell death that is known as a “cell death” and which has been associated with Parkinson’s disease for more than 40 years.
Journal ArticleDOI
An epidemic, toxin gene-variant strain of Clostridium difficile.
L. Clifford McDonald,George Killgore,Angela Thompson,Robert C. Owens,Sophia Kazakova,Susan P. Sambol,Stuart Johnson,Dale N. Gerding +7 more
TL;DR: A previously uncommon strain of C. difficile with variations in toxin genes has become more resistant to fluoroquinolones and has emerged as a cause of geographically dispersed outbreaks of C.'s Difficile-associated disease.
Journal ArticleDOI
Antimicrobial-Associated Risk Factors for Clostridium difficile Infection
Robert C. Owens,Curtis J. Donskey,Robert P. Gaynes,Robert P. Gaynes,Vivian G. Loo,Carlene A. Muto +5 more
TL;DR: Investigations involving animal models and studies performed in vitro suggest that inhibitory activity against C. difficile and differences in the propensity to stimulate toxin production may also influence the likelihood that particular drugs may cause CDI.
Journal ArticleDOI
Antimicrobial safety: focus on fluoroquinolones.
Robert C. Owens,Paul G. Ambrose +1 more
TL;DR: The currently marketed quinolones are well tolerated, with safety profiles similar to those of other antimicrobial classes, although adverse effects are unusual, some, including tendinitis and CNS-related effects, are more common with quInolones than with other antimacterial classes.
Journal ArticleDOI
Measures to control and prevent Clostridium difficile infection.
TL;DR: Good antimicrobial stewardship complements infection control efforts and environmental interventions to provide a comprehensive strategy to prevent and control outbreaks of CDI.